摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-amino-2-(5-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-7-methylbenzofuran-2-yl)propane-1,3-diol | 1608144-21-3

中文名称
——
中文别名
——
英文名称
2-amino-2-(5-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-7-methylbenzofuran-2-yl)propane-1,3-diol
英文别名
2-Amino-2-[5-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-7-methyl-1-benzofuran-2-yl]propane-1,3-diol
2-amino-2-(5-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-7-methylbenzofuran-2-yl)propane-1,3-diol化学式
CAS
1608144-21-3
化学式
C24H27N3O6
mdl
——
分子量
453.495
InChiKey
WQQUFVNZMVJKGC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    33
  • 可旋转键数:
    9
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    137
  • 氢给体数:
    3
  • 氢受体数:
    9

文献信息

  • [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
    申请人:AKAAL PHARMA PTY LTD
    公开号:WO2014063199A1
    公开(公告)日:2014-05-01
    Novel benzofuran derivatives are disclosed. The derivatives have S1P1 receptor activity and/or disease modifying activity and find use in the treatment of conditions or diseases associated with the immune, vascular and nervous systems in animals and/or humans
    揭示了新型苯并呋喃生物。这些衍生物具有S1P1受体活性和/或疾病修饰活性,并可用于治疗与动物和/或人类的免疫、血管和神经系统相关的疾病或症状。
  • S1P Receptors Modulators and Their Use Thereof
    申请人:Gill Gurmit S.
    公开号:US20110318388A1
    公开(公告)日:2011-12-29
    The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.
    本发明涉及具有S1P受体调节活性的新化合物。此外,本发明涉及包括本发明中至少一种化合物的药物,用于治疗由不适当的S1P受体调节活性或表达引起或相关的疾病和/或病情,例如自身免疫反应。本发明的另一个方面涉及使用包括本发明中至少一种化合物的药物制造药物,用于治疗由不适当的S1P受体调节活性或表达引起或相关的疾病和/或病情,例如自身免疫反应。
  • S1P RECEPTORS MODULATORS AND THEIR USE THEREOF
    申请人:AKAAL PHARMA PTY LTD.
    公开号:US20160038455A1
    公开(公告)日:2016-02-11
    The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.
    本发明涉及具有S1P受体调节活性的新化合物。此外,本发明涉及一种制药组合物,包括本发明中的至少一种化合物,用于治疗由于或与不当的S1P受体调节活性或表达有关的疾病和/或病症,例如自身免疫反应。本发明的另一个方面涉及使用包括本发明中的至少一种化合物的制药组合物制造用于治疗由于或与不当的S1P受体调节活性或表达有关的疾病和/或病症,例如自身免疫反应的药物。
  • US8592399B2
    申请人:——
    公开号:US8592399B2
    公开(公告)日:2013-11-26
  • US9193716B2
    申请人:——
    公开号:US9193716B2
    公开(公告)日:2015-11-24
查看更多